Pfizer’s Phase III ALO-02 Trial Meets Endpoint

Pfizer reported top-line results from a Phase III study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain. ALO-02 met the primary efficacy endpoint, demonstrating a statistically significant benefit from placebo. The most common adverse events with ALO-2 during the double-blind period in this study were nausea, vomiting and diarrhea.